Welcome to our newly formatted LifeSciences BC newsletter!
With the support and valuable contribution from Coast Communications we decided it was time for a redo of our weekly newsletter. We hope you enjoy the updated content and as always, would love to hear from you! Please share your life science news with us by sending it to
sogilvie@lifesciencesbc.ca
.
|
|
|
|
Minister Bains announces members of new Industry Strategy Council
|
June 2, 2020 – Ottawa, Ontario The Government of Canada recognizes that a smooth economic recovery will require continued collaboration between the public and private sectors in the wake of the direct effects, changes and adaptations related to COVID-19.
READ MORE
|
|
|
|
InMed Announces Filing of Registration Statement in Connection with United States Offering, Application to Seek Nasdaq Listing and Planned Share Consolidation
|
Vancouver, BC – June 19, 2020 A clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (“CBN”), today announced that it has filed a registration statement on Form S-1 with the United States Securities and Exchange Commission...
READ MORE
|
|
|
|
Neoleukin Therapeutics Presents Preclinical Data for NL-201 and De Novo Protein Design Technology at American Association for Cancer Research (AACR) Virtual Annual Meeting II
|
SEATTLE, June 22, 2020 (GLOBE NEWSWIRE) — Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de Novo protein therapeutics, today announced....
READ MORE
|
|
|
|
DelMar Pharmaceuticals Presents Positive Interim Data on VAL-083 Demonstrating Favorable Outcomes in Both Newly- Diagnosed and Recurrent GBM at the AACR Virtual Annual Meeting II
|
SAN DIEGO, June 22, 2020 /PRNewswire/ —
DelMar Pharmaceuticals, Inc.
(Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced positive interim data from its two Phase 2 trials of VAL-083 for the treatment of glioblastoma multiforme (GBM)
READ MORE
|
|
|
|
Aurinia Completes Patient Enrollment Into the AUDREY Phase 2/3 Clinical Trial of Voclosporin Ophthalmic Solution for the Treatment of Dry Eye Syndrome
|
VICTORIA, British Columbia–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (Nasdaq: AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple indications, today announced it has completed enrollment for the Phase 2/3 AUDREY™ clinical trial evaluating voclosporin ophthalmic solution (VOS) for the potential treatment of dry eye syndrome
READ MORE
|
|
Presenting LifeSciences BC's Newest Members
|
|
LifeSciences BC would like to welcome Alpha 9 Therapeutics and Kardium as our newest members this week!
|
|
Deloitte’s FAST 50 Program - Sponsored by RBC
|
|
Enterprise 15
– Open to companies with a minimum revenue of $10 million in 2016 and a minimum revenue of $25 million in 2019
|
|
|
|
We Want to Hear from You!
The COVID-19 pandemic has challenged and changed our province. Across B.C., we have been touched by job loss and change, health concerns, worries about how our families and communities can cope, and increasing uncertainty about the future.
Read More
|
|
|
|
Canada may be losing its status as a top global destination for new medicine launches
|
TORONTO, June 25, 2020 /CNW/ - Canada has long been considered a top global jurisdiction for new medicine launches. However, a new report published by Life Sciences Ontario (LSO) shows that new medicine launches in Canada fell dramatically in 2019.
READ MORE
|
|
|
|
Posting A JOB on the LSBC Website
|
LSBC Membership Discounts on Job Postings
As an LSBC member, your first five job postings EARNS a free repost on Biotalent Canada's
The Petri Dish
?
After your first five reposts, you will also receive 25% off all job postings on
The Petri Dish
. Want more info?
|
|
|
|
|
|
|
